Concepedia

Author

Jaret Malloy

Eli Lilly (United States)ORCID

Also Known As

J Malloy, J. Malloy, J.L. Malloy, JARET MALLOY, Jaret L Malloy, Jaret L. Malloy, Jaret Malloy

47

Publications

2.9K

Citations

21

H-Index

28

Concepts

All Affiliations

Eli Lilly (United States)Lawson Health Research InstituteWestern UniversityZafgen (United States)St Joseph's Health Centre
JM

About

Jaret Malloy is an author at Eli Lilly (United States) specializing in medicine, diabetes, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

1K

2

Diabetes

4

4

814

3

Immunology

2

2

143

4

Allergy

1

1

13

5

Biochemistry

1

1

44

Jaret Malloy

×

26

Publications

2.6K

Citations

21

H-Index

YearCitations

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, Carol Wysham, Leigh MacConell,

The Lancet

2010

605

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy,

The Journal of Clinical Endocrinology & Metabolism

2011

442

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Mathijs C. Bunck, Michaëla Diamant, A. H. Corner,

Diabetes Care

2009

385

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Bruno Guerci,

The Lancet Diabetes & Endocrinology

2014

152

<i>Pseudomonas aeruginosa</i>protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions

Jaret Malloy, Ruud A. W. Veldhuizen, Brett A. Thibodeaux,

American Journal of Physiology-Lung Cellular and Molecular Physiology

2004

130

DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide

Carol Wysham, Richard M. Bergenstal, Jaret Malloy,

Diabetic Medicine

2011

117

Effects of <scp>MetAP2</scp> inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial

Shawn E. McCandless, Jack A. Yanovski, Jennifer Miller,

Diabetes Obesity and Metabolism

2017

103

Glutathione Replacement Preserves the Functional Surfactant Phospholipid Pool Size and Decreases Sepsis‐Mediated Lung Dysfunction in Ethanol‐Fed Rats

Alvaro Velasquez, Rabih Bechara, James F. Lewis,

Alcoholism Clinical and Experimental Research

2002

73

Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials

Michael Grimm, Jenny Han, Carole Weaver,

Postgraduate Medicine

2013

63

Alterations of the Endogenous Surfactant System in Septic Adult Rats

Jaret Malloy, Lynda McCaig, Ruud A. W. Veldhuizen,

American Journal of Respiratory and Critical Care Medicine

1997

60

Page 1